# An Open Label Dose Escalation Study Of E7080

> **NCT00121719** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 82 (actual)

## Conditions studied

- Solid Tumor or Lymphoma

## Interventions

- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT00121719
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07-01
- **Primary completion:** 2009-06-19
- **Final completion:** 2019-03-01
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121719, "An Open Label Dose Escalation Study Of E7080". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT00121719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*